Atypical chemokine receptor CCRL2 is overexpressed in prostate cancer cells

Abstract

Atypical chemokine receptors have recently emerged as important molecular players in health and diseases; they affect chemokine availability and function and impact a multitude of pathophysiological events, including the tumorigenesis process. This family of atypical receptors comprises five members: ACKR1/DARC, ACKR2/D6, ACKR3/CXCR7, ACKR4/CCRL1, and ACKR5/CCRL2. This work evaluated the differential expression of these receptors in prostate cancer using quantitative PCR. Further evaluation of CCRL2 at the protein level confirmed its overexpression in a metastatic cell line and in malignant prostatic tissues from patients. CCRL2, a presumed member of the atypical chemokine receptor family, plays a key role in lung dendritic cell trafficking to peripheral lymph nodes. Recent studies have reported the expression of CCRL2 in different human cancer cell lines and tissues. However, its function and expression in prostate cancer has not been previously addressed.

Keywords

chemokine receptor / prostatic neoplasms / CCRL2 receptor / real-time polymerase chain reaction / tissue array analysis

References

[1] Sokol CL, Luster AD. The chemokine system in innate immunity[J]. Cold Spring Harb Perspect Biol, 2015, 7(5): a016303

[2] Rollins BJ. Chemokines[J]. Blood, 1997, 90(3): 909–928

[3] Rossi D, Zlotnik A. The biology of chemokines and their receptors[J]. Annu Rev Immunol, 2000, 18: 217–242.

[4] Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity[J]. Immunity, 2000, 12(2): 121–127

[5] Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity[J]. Annu Rev Immunol, 2014, 32: 659–702

[6] Horuk R. Chemokine receptors[J]. Cytokine Growth Factor Rev, 2001, 12(4): 313–335

[7] Bachelerie F, Ben-Baruch A, Burkhardt AM, International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors[J]. Pharmacol Rev, 2013, 66(1): 1–79

[8] Bachelerie F, Graham GJ, Locati M, New nomenclature for atypical chemokine receptors[J]. Nat Immunol, 2014, 15(3): 207–208

[9] Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases[J]. Blood, 2000, 95(10): 3032–3043

[10] Rajagopalan L, Rajarathnam K. Structural basis of chemokine receptor function--a model for binding affinity and ligand selectivity[J]. Biosci Rep, 2006, 26(5): 325–339

[11] Ulvmar MH, Hub E, Rot A. Atypical chemokine receptors[J]. Exp Cell Res, 2011, 317(5): 556–568

[12] Bonecchi R, Graham GJ. Atypical chemokine receptors and their roles in the resolution of the inflammatory response[J]. Front Immunol, 2016, 7: 224

[13] Hou T, Liang D, Xu L, Atypical chemokine receptors predict lymph node metastasis and prognosis in patients with cervical squamous cell cancer[J]. Gynecol Oncol, 2013, 130(1): 181–187

[14] Massara M, Bonavita O, Mantovani A, Atypical chemokine receptors in cancer: friends or foes[J]? J Leukoc Biol, 2016, 99(6): 927–933

[15] Nibbs RJ, Graham GJ. Immune regulation by atypical chemokine receptors[J]. Nat Rev Immunol, 2013, 13(11): 815–829

[16] Patel M, McInnes IB, Graham G. Atypical chemokine receptors in inflammatory disease[J]. Curr Mol Med, 2009, 9(1): 86–93

[17] Yoshimura T, Oppenheim JJ. Chemokine-like receptor 1 (CMKLR1) and chemokine (C-C motif) receptor-like 2 (CCRL2); two multifunctional receptors with unusual properties[J]. Exp Cell Res, 2011, 317(5): 674–684.

[18] Monnier J, Lewén S, O’Hara E, Expression, regulation, and function of atypical chemerin receptor CCRL2 on endothelial cells[J]. J Immunol, 2012, 189(2): 956–967

[19] Wang LP, Cao J, Zhang J, The human chemokine receptor CCRL2 suppresses chemotaxis and invasion by blocking CCL2-induced phosphorylation of p38 MAPK in human breast cancer cells[J]. Med Oncol, 2015, 32(11): 254

[20] Akram IG, Georges R, Hielscher T, The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis[J]. Tumour Biol, 2016, 37(2): 2461–2471

[21] Yin F, Xu Z, Wang Z, Elevated chemokine CC-motif receptor-like 2 (CCRL2) promotes cell migration and invasion in glioblastoma[J]. Biochem Biophys Res Commun, 2012, 429(3-4): 168–172

[22] Mays AC, Feng X, Browne JD, Chemokine and chemokine receptor profiles in metastatic salivary adenoid cystic carcinoma[J]. Anticancer Res, 2016, 36(8): 4013–4018

[23] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) method[J]. Methods, 2001, 25(4): 402–408

[24] Fedor HL, De Marzo AM. Practical methods for tissue microarray construction[J]. Methods Mol Med, 2005, 103: 89–101

[25] Szabo MC, Soo KS, Zlotnik A, Chemokine class differences in binding to the Duffy antigen-erythrocyte chemokine receptor[J]. J Biol Chem, 1995, 270(43): 25348–25351

[26] Belperio JA, Keane MP, Arenberg DA, CXC chemokines in angiogenesis[J]. J Leukoc Biol, 2000, 68(1): 1–8

[27] Strieter RM, Polverini PJ, Kunkel SL, The functional role of the ELR motif in CXC chemokine-mediated angiogenesis[J]. J Biol Chem, 1995, 270(45): 27348–27357

[28] Ferrer FA, Miller LJ, Andrawis RI, Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells[J]. Urology, 1998. 51(1): 161–167.

[29] Wang J, Ou ZL, Hou YF, Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential[J]. Oncogene, 2006, 25(54): 7201–7211

[30] Wu FY, Fan J, Tang L, Atypical chemokine receptor D6 inhibits human non-small cell lung cancer growth by sequestration of chemokines[J]. Oncol Lett, 2013, 6(1): 91–95

[31] Parsi B, Esmaeili A, Hashemi M, Transient expression of recombinant ACKR4 (CCRL1) gene, an atypical chemokine receptor in human embryonic kidney (HEK 293) cells[J]. Mol Biol Rep, 2016, 43(7): 583–589

[32] Burns JM, Summers BC, Wang Y, A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development[J]. J Exp Med, 2006, 203(9): 2201–2213

[33] Sun X, Cheng G, Hao M, CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression[J]. Cancer Metastasis Rev, 2010, 29(4): 709–722

[34] Maishi N, Ohga N, Hida Y, CXCR7: a novel tumor endothelial marker in renal cell carcinoma[J]. Pathol Int, 2012, 62(5): 309–317

[35] Pontén F, Jirström K, Uhlen M. The human protein atlas-a tool for pathology[J]. J Pathol, 2008, 216(4): 387–393

Acknowledgments

The authors are thankful to the Department of Pathology of the Hospital Universitario del Caribe for providing the tissue samples; to Dr. Angelo De Marzo from Johns Hopkins University School of Medicine, for all the support in TMA construction and processing.

RIGHTS & PERMISSIONS

2018 2018 by the Journal of Biomedical Research.